mTOR-inhibition in metastatic renal cell carcinoma. Focus on temsirolimus: A review

Minerva Urologica e Nefrologica

Volumn 62, Issue 4, 2010, Pages 411-423

  Gerullis, H ^a,b,c   Ecke, T H ^c   Eimer, C ^a,c   Heuck, C J ^d   Otto, T ^a,b,c  

^a Lukaskrankenhaus GmbH   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c HELIOS Klinikum Bad Saarow   (Germany)

^d ALBERT EINSTEIN CANCER CENTER   (United States)

Author keywords

Quality of life; Renal cell carcinoma; Targeted therapy; Temsirolimus, mTOR

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAPAMYCIN; SORAFENIB; TEMSIROLIMUS; TIVOZANIB;

ADVANCED CANCER; ANEMIA; ANOREXIA; ASTHENIA; CANCER PALLIATIVE THERAPY; CARDIOTOXICITY; CREATININE BLOOD LEVEL; CYTOPENIA; DEPRESSION; DISEASE FREE INTERVAL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INFECTION; INTERSTITIAL PNEUMONIA; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PAIN; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; VOMITING;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; HUMANS; KIDNEY NEOPLASMS; QUALITY OF LIFE; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79952061529     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. SEER Cancer Statistics Review, 1975-2005, National Cancer Institute [Internet]. Bethesda, MD. Available from http://seer.cancer.gov/csr/1975-2005/, based on November 2007 SEER data submission, posted to the SEER web site [database on the Internet] 2008 [cited 2010, May 24, 2010].
3. Larkin JMG, Chowdhury S, Gore ME. Drug insight: advances refractory renal cell carcinoma and the role of targeted therapies. Nat Clin Pract Oncol 2007;4:470-9.
4. Pantuck AJ, Zisman A, Belldegrun A. The changing natural history of renal cell carcinoma. J Urol 2001;166: 1611-23.
5. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer Statistics, 2008. CA Cancer J Clin 2008;58:71-96.
6. National Cancer Care Network. Kidney cancer V.1 [Internet]. Available from www.nccn.org/professionals/physician-gls/PDF/kidney.pdf [cited 2008, Mar 1].
7. Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PF, Patard JJ et al. European Association of Urology Guideline Group for renal cell carcinoma. Renal cell carcinoma guideline. Eur Urol 2007;51:1502-10.
8. Froehner M, Hakenberg OW, Wirth MP. Molecular therapy in urologic oncology. Urol Int 2007;79:1-7.
9. Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz EM. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18:1928-35. (Pubitemid 30261931)
10. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber, DJ, Hwu P et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;15:3127-32.
11. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005;CD001425.
12. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-40. (Pubitemid 29368255)
13. Négrier S, Escudier B, Gomez F, Douillard JY, Ravaud A, Chevreau C et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann Oncol 2002;13:1460-8.
14. Negrier S, Perol D, Ravaud A, Chevreau C, Bay JO, Delva R et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial. Proc Am Soc Clin Oncol 2005;23:16S (Abstract 4511).
15. Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol 2003;170:2163-72.
16. Geffen DB, Man S. New drugs for the treatment of cancer, 1990-2001. Isr Med Assoc J 2002;4:1124-31.
17. Dassonville O, Bozec A, Fischel JL, Milano G. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. Crit Rev Oncol Hematol 2007;62:53-61. (Pubitemid 46330798)
18. Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J et al. Targeted therapies for cancer 2004. Am J Clin Pathol 2004;122:598-609.
19. Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal carcinoma. J Clin Oncol 2006;24:5601-8. (Pubitemid 46631341)
20. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24. (Pubitemid 46089672)
21. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebeis M et al. TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34. (Pubitemid 46089673)
22. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81. (Pubitemid 46849157)
23. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.
24. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;37:2103-11. (Pubitemid 350296300)
25. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002;22:7004-14.
26. Bardos JI, Ashcroft M. Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays 2004;26:262-9.
27. Yu Y, Sato JD. MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor. J Cell Physiol 1999;178:235-46.
28. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994;91:9700-4. (Pubitemid 24311875)
29. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc NatlAcad Sci USA 2000;97:10430-5.
30. Shegal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. Fermentation, isolation and characterization. J Antibiot (Tokyo) 1975;28:727-32.
31. Peralba JM, DeGraffenried L, Friedrichs W, Fulcher L, Grünwald V, Weiss G et al. Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients. Clin Cancer Res 2003;9:2887-92. (Pubitemid 36993245)
32. Brown EI, Beal PA, Keith CT, Chen J, Shin TB, Schreiber SL. Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature 1995;377:441-6.
33. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999;96:4240-5. (Pubitemid 29190320)
34. Lam JS, Leppert JT, Figlin RA, Belidegrun AS. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology 2005;66(suppl.):1-9. (Pubitemid 41356552)
35. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001;98:10314-9. (Pubitemid 32803017)
36. Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004;22:2336-47. (Pubitemid 41115390)
37. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22: 909-18. (Pubitemid 41103603)
38. Wyeth Pharmaceuticals Inc Full prescribing information: Torisel™ [Internet]. Available from URL: http://www.wyeth.com/content/ShowLabeling.asp? id=490 [cited 2010, May 24].
39. Boni JP, Leister C, Burns J, M. Cincotta, B. Hug, and L. Moore. Pharmacokinetics profile of temsirolimus (CCI-779) IV with concomitant administration cytochrome P450-inducing medications [abstract PII-84] Clin Pharmacol Ther 2007;81(Suppl. 1):76
40. Wyeth Europa Ltd. Torisel(temsirolimus): summary of product characteristics [Internet]. Available from URL:http://www.emea.europa.eu/ humandocs/Humans/EPAR/torisel/torisel.htm [cited 2010, May 24].
41. Torisel (temsirolimus) package insert. Revised September 2008. Available from www.wyeth.com/content/ showlabelingasp?id=490 [cited 2008, Nov 11].
42. Boni JP, Leister C, Bender G, Fitzpatrick V, Twine N, Stover J et al. Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clin Pharmacol Ther 2005;77:76-89. (Pubitemid 40075391)
43. Lunardi G, Vannozzi MO, Armirotti A, Nicodemo M, Venturini M, Cavallini L. Temsirolimus in patients with renal cancer on hemodialysis. J Clin Oncol 2008;26: 5652-3.
44. Motzer RJ, Hudes GR, Curti BD, McDermott DF, Escudier BJ, Negrier S et al. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol 2007;25:3958-64. (Pubitemid 47477274)
45. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22:454-63. (Pubitemid 41079774)
46. Figlin RA, de Souza P, McDermott D, Dutcher JP, Berkenblit A, Thiele A et al. Analysis of PTEN and HIF-1a and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus Interferon-a. Cancer 2009;115:3651-60.
47. Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007;109:2257-67. (Pubitemid 46801555)
48. Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, Hutterer G et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008;53:917-30.
49. Bellmunt J, Szczylik C, Feingold J, Strahs A, Berkenblit A. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 2008;19:1387-92.
50. Boni J, Leister C, Bender G, Fitzpatrick V, Twine N, Stover J et al. Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clin Pharmacol Ther 2005;77:76-89. (Pubitemid 40075391)
51. Buhaescu I, Izzedine H, Covic A Sirolimus-challenging current perspectives. Ther Drug Mon it 2006;28:577-84.
52. Gerullis H, Bergmann L, Maute L, Eimer C, Otto T. Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany. Cancer Chemother Pharmacol 2009;63:1097-102.
53. Pelz H, Krekeler G, Bergmann L. Evaluation of safety, tolerability and activity: a registry for Temsirolimus-treated patients with advanced or metastatic renal cell carcinoma (aRCC) in the usual health care setting. Eur Urol Suppl 2009;8:156.
54. Chowdhury S, Larkin JM, Gore ME. Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies. Eur J Cancer 2008;44:2152-61.
55. Wysocki PJ, Zolnierek J, Szczylik C, Mackiewicz A. Targeted therapy of renal cell cancer. Curr Opin Investig Drugs 2008;9:570-5. (Pubitemid 351777160)
56. Revicki DA, Feeny D, Hunt TL, Cole BF. Analyzing oncology clinical trial data using the Q-TWiST method: clinical importance and sources for health state preference data. Qual Life Res 2006;15:411-23.
57. Stephens R. Clinically important differences in Q-TWI-ST - one twist too many? Qual Life Res 2006;15:425-8.
58. Sloan JA, Sargent DJ, Lindman J, Allmer C, Vargas-Chanes D, Creagan ET et al. A new graphic for quality adjusted life years (Q-TWiST) survival analysis: the Q-TWiST plot. Qual Life Res 2002;11:37-45. (Pubitemid 34293385)
59. Mounier N, Ferme C, Flechtner H, Henzy-Amar M, Lepage E. Model-based methodology for analyzing incomplete quality-of-life data and integrating them into the Q-TWiST framework. Med Decis Making 2003;23:54-66. (Pubitemid 36133360)
60. Rusthoven JJ. Are quality of life, patient preferences, and costs realistic outcomes for clinical trials? Support Care Cancer 1997;5:112-7.
61. Parasuraman S, Hudes G, Levy D, Strahs A, Moore L, Demetri GD et al. Comparison of quality- adjusted survival in patients with advanced renal cell carcinoma receiving first- line treatment with temsirolimus (TEM-SR) or interferon-α (IFN) or the combination of IFN + TEMSR. J Clin Oncol 2007;25:5049.
62. Ravaud A. Key considerations in patient selection for the use of targeted therapy in metastatic renal cell carcinoma. Eur J Cancer Suppl 2007;5:20-7. (Pubitemid 350017072)
63. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96. (Pubitemid 34032623)
64. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer [Internet]. Available from http://www.nccn.org [cited 2010, Nay 24].
65. de Reijke TM, Bellmunt J, van Poppel H, Marreaud S, Aapro M. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer 2009;45:765-73.
66. Bellmunt J, Négrier S, Escudier B, Awada A, Aapro M; SIOG Taskforce. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOGTaskforce. Crit Rev Oncol Hematol 2008;69:64-72.
67. Rini BI. Metastatic renal cell carcinoma: many treatment options, one patient. J Clin Oncol 2009;27:3225-34.
68. Patel PH, Senico PL, Ouriel RE, Motzer RJ. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2009;7:24-7.
69. Gerullis H, Bergmann L, Maute L, Ecke TH, Eimer C, Bagner JW et al. Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma. Med Oncol 2009 doi: 10.1007/S12032-009-9220-1
70. Dutcher JP, de Souza P, McDermott D, Figlin RA, Berkenblit A, Thiele A et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009;26:202-9.
71. Eichelberg C, Heuer R, Chun FK, Hinrichs K, Zacharias M, Huland H et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol 2008;54:1373-8.
72. Tamaskar I, Garcia JA, Elson P, Wood L, Mekhail T, Dreicer R et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008;179:81-6. (Pubitemid 350216728)
73. Study comparing bevacizumab + temsirolimus vs bevacizumab + interferon-alfa in advanced renal-cell carcinoma subjects. Accessed December 2008. Clinical Trials.gov http://clinicaltrials.gov/ct2/show/NCT00631371?term= bevacizumab+temsirolimus+IFN&rank=1
74. Temsirolimus versus sorafenib as second-line therapy in patients with advanced RCC who have failed first-line sunitinib. Accessed December 2008, Available at Clinical Trials.gov web site, http://clinicaltrials.gov/ct2/show/ NCT00474786?term=temsirolimus+sorafenib+sunitinib&rank=1